The QualityStocks Daily Thursday, March 17th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(BNOW) $0.0057 +714.29%

SmallCapRelations(MULN) $2.4400 +39.43%

Schaeffer's(PD) $32.4500 +20.86%

The QualityStocks Daily Stock List

Boon Industries (BNOW)

QualityStocks, Penny Picks and Damn Good Penny Picks reported earlier on Boon Industries (BNOW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Boon Industries Inc. (OTC: BNOW) is a bioscience firm that is engaged in the development, manufacture and marketing of specialty water-soluble ingredients with patented formulations that cater to the nutraceutical, beverage and food industries internationally as well as in the U.S.

The firm has its headquarters in Grass Valley, California and was incorporated in 2020, on March 2nd.

The enterprise provides an active biocide known as DiOx+, which doesn’t leave residual toxicity or form any toxic by-products; a water based mineral supplement and electrolyte concentrate dubbed M+ which helps deliver calcium, sodium, potassium and magnesium and a water soluble hemp extract ingredient known as H+, which is utilized in various formulations marketed as Energy, Relax and Sleep. Its DiOx+ product is a chlorine dioxide disinfectant/sterilizer that is used in water treatment systems and in food processing. This product is distributed under the Biodox brand name.

In addition to this, the company offers a global sourcing platform that facilitates the development and sourcing of retail branded and private label products for retailers and their network of service providers, agents and suppliers. It provides an on-demand enterprise solution for the issues of global sourcing. Under this, the company operates in the technology sector, under the software and tech services industry, in the software sub-industry.

The firm recently announced that it would be proceedings with some of its targeted sales initiatives which will bring in revenue from the crop protection market in North America, which is valued at $11 billion. Its CEO noted that their DiOx+ product, which was recently trademarked, would be the main product generating revenue from the agriculture sector and would help bring in important investors.

Boon Industries (BNOW), closed Thursday’s trading session at $0.0057, up 714.2857%, on 1,375,465,674 volume. The average volume for the last 3 months is 1.375B and the stock's 52-week low/high is $0.0006/$0.159.

Cuentas, Inc. (CUEN)

QualityStocks, MarketClub Analysis, StocksEarning, TopPennyStockMovers and BUYINS.NET reported earlier on Cuentas, Inc. (CUEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cuentas, Inc. is a top FinTech (Financial Technology) provider of mobile banking and payment solutions serving Latino and Hispanic consumers. The Company uses technical innovation together with existing and emerging technologies to deliver accessible, efficient, and reliable mobile, new-era and traditional financial services to consumers. The Company has its proprietary Cuentas General Purpose Reloadable (GPR) Card. Cuentas has its head office in Miami, Florida and the Company’s shares trade on the OTC Markets Group’s OTCQB.

Cuentas uses technology to bridge the gap between traditional financial services and the underbanked U.S. Latino population. The Company’s services include, but are not limited to, mobile banking, online banking, prepaid debit, bill pay, ACH and mobile deposits, cash remittance, peer to peer money transfer, and bank accounts to customers who previously could not obtain bank accounts.

The Cuentas General Purpose Reloadable (GPR) Card provides holders with digital wallets, discounts for purchases at major physical and online retailers, free telecom, and the ability to purchase digital content. The card will be available in more than 31,000 bodegas.

The Cuentas Fintech Card is an online bank account integrated with the Cuentas branded general purpose reloadable card (GPR). It provides a total online banking solution to all, including those without a U.S. government issued ID.

Cuentas has begun a methodical and controlled rollout of the Cuentas Prepaid GPR card. It is at the same time improving the app through new features and capabilities, and also adding many more physical reloading locations.

Concerning Mobile Wallet, the in-app Mobile Wallet offers FinTech Card functionality for online and mobile purchases. The Cuentas Virtual Marketplace provides discounted gift cards to Cuentas cardholders. These can be stored in the Cuentas Mobile Wallet and be used online, sent electronically to friends or family, and redeemed for a physical gift card.

Cuentas, Inc. (CUEN), closed Thursday’s trading session at $1.7, up 54.5455%, on 1,879,282 volume. The average volume for the last 3 months is 1.879M and the stock's 52-week low/high is $0.80/$9.25.

Brewbilt Brewing Co. (BRBL)

We reported earlier on Brewbilt Brewing Co. (BRBL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Brewbilt Brewing Co. is one of the only California companies that custom designs, hand crafts, and integrates processing, fermentation, and distillation processing systems for the craft beer, cannabis, and hemp industries. The Company uses "Best in Class" U.S. made components integrated with stainless steel processing vessels using only American made steel. BrewBilt Manufacturing’s dedication is to helping build the craft beer community one brewery at a time. Founded in 2014, BrewBilt Manufacturing is headquartered in Grass Valley, California. The Company lists on the OTC Markets.

All BrewBilt products are designed and fabricated as "food grade" quality. This enables the Company to manufacture vessels for food & beverage processing. BrewBilt has been making systems that are pharmaceutical grade for clients involved in distillation for the cannabis and hemp industries over the past 36 months, thus making the revenue potential considerably greater.

The Company works with its clients every step of the way. This is from concept to opening. BrewBilt helps its clients keep on track. This is from working with their bankers on financing solutions, their architect and contractor on equipment layout, to scheduling, logistics, and continuing project management.

BrewBilt provides a six-year material and workmanship warranty on everything it builds. The BrewBilt team includes brewers, design engineers, craftsmen, and owners with greater than 50 years of business experience.

Recently, BrewBilt announced that it will officially compete as a part of the $500B beer brewing industry in 2021. With its new strategic partnership, it has agreed to immediately fulfill craft beer orders in China, Finland, as well as San Francisco.

Brewbilt Brewing Co. (BRBL), closed Thursday’s trading session at $0.0017, up 54.5455%, on 181,865,944 volume. The average volume for the last 3 months is 181.866M and the stock's 52-week low/high is $0.00105/$0.30.

TD Holdings (GLG)

MarketBeat, StockMarketWatch, QualityStocks, TopPennyStockMovers, Stock Traders Chat, SmallCapVoice, Money Morning, MicroCap Press, Market Wrap Daily, Investor Guide, FreeRealTime and BestOtc reported earlier on TD Holdings (GLG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TD Holdings Inc. (NASDAQ: GLG) (FRA: CNG1) is a holding firm that is engaged in the commodities supply chain and trading business.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2011, on December 19th. Prior to its name change in March 2020, the firm was known as Bat Group Inc. It operates as a part of the retail and wholesale discretionary industry, under the consumer discretionary sector, in the retail-discretionary sub-industry and serves consumers in China.

The company operates through the Supply Chain Management services, Commodity Trading. and Used Car Leasing business segments. It mainly conducts its business in Hebei, Tianjin and Beijing, China and serves as a digital intelligence supply chain platform and a one-stop commodity supply chain service integrating futures trading, information, logistics, warehouses, upstream and downstream enterprises.

The enterprise leases a variety of types and brands of used luxurious cars under the Batcar brand. Its supply chain service covers various commodities, such as wood, rubber, oils, soybean oils, metallurgical raw materials, coal, ferrous metals and non-ferrous metals, as well as other types of commodities. On the other hand, the enterprise’s commodity trading business is involved in the purchase of non-ferrous metal products, including gold, silver, copper and aluminum ingots from mineral and upstream metal suppliers and selling them to downstream consumers.

The company recently entered into a strategic framework agreement with Sinotech Minerals Exploration Co. Ltd. This will help TD Holdings integrate and develop global mineral resources while it also consolidates its influence and position in the mining sector. The company plans to expand into upstream resources in the near future and is focused on improving its profitability, which will boost its growth as well as attract investments into the company.

TD Holdings (GLG), closed Thursday’s trading session at $0.33, up 39.0645%, on 83,790,427 volume. The average volume for the last 3 months is 80.746M and the stock's 52-week low/high is $0.17/$2.43.

Synthetic Biologics (SYN)

StockMarketWatch, Streetwise Reports, Stock Analyzer, MarketBeat, Wall Street Resources, TradersPro, BUYINS.NET, StockOodles, INO.com Market Report, StreetInsider, The Street, StreetAuthority Daily, Investors Alley, Top Stock Picks, InvestorPlace, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, BestOtc, Investing Lab, Barchart, Marketbeat.com, PennyOmega, AwesomeStocks, QualityStocks, Zacks, StockHotTips, SuperNova Elite, The Online Investor, TopPennyStockMovers, TopStockAnalysts and PennyToBuck reported earlier on Synthetic Biologics (SYN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Synthetic Biologics Inc. (NYSE American: SYN) (FRA: SFYC) is a clinical-stage firm that is focused on the development of therapeutics for the treatment of gastrointestinal ailments.

The firm has its headquarters in Rockville, Maryland and was incorporated in January 2001 by Steven H. Kanzer. It serves consumers in the United States.

The company is party to a clinical trial agreement with the Washington University School of Medicine in St. Louis, which involves a phase 2 clinical trial of the company’s SYN-004 candidate. It is also party to collaboration agreements with Cedars-Sinai Medical Center, the University of Texas at Austin and Intrexon Corporation.

The enterprise’s product pipeline comprises of a recombinant oral formulation dubbed SYN-020, indicated for the treatment of both systemic and local gastrointestinal illnesses; SYN-005, which has been developed to prevent and treat pertussis; SYN-006 and SYN-007, which have both been developed to prevent the emergence of antimicrobial resistance, overgrowth of pathogenic organisms and clostridium difficile infection. In addition to this, the enterprise develops SYN-004, which concluded phase 2 trials to degrade intravenous beta-lactam antibiotics in the gastrointestinal tract for the prevention of acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients, the emergence of antimicrobial resistance, overgrowth of pathogenic organisms, clostridium difficile infection and microbiome damage.

The company recently expanded its exclusive license agreement with the Massachusetts General Hospital to include technology and intellectual property related to the use of its SYN-020 candidate in inhibiting liver fibrosis in some indications. The success of this formulation would address a significantly unmet need for innovative therapies that target gastrointestinal disorders, which would have a positive effect not only the company’s growth but also its revenue.

Synthetic Biologics (SYN), closed Thursday’s trading session at $0.3468, up 37.5645%, on 30,898,639 volume. The average volume for the last 3 months is 29.623M and the stock's 52-week low/high is $0.215/$0.859.

Marrone Bio Innovations (MBII)

MarketBeat, StreetInsider, TraderPower, TopPennyStockMovers, Street Insider, Investing Futures, Marketbeat.com, Stock Market Watch, FreeRealTime, InvestorPlace, QualityStocks, equities Canada, Short Term Wealth, Trades Of The Day, StockOodles, The Street and SECFilings.com News reported earlier on Marrone Bio Innovations (MBII), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marrone Bio Innovations Inc. (NASDAQ: MBII) (FRA: 0MB) is a biopesticide firm that is focused on the discovery, development, production and promotion of biological products for plant health, plant nutrition and pest management.

The firm has its headquarters in Davis, California and was incorporated in 2006, on June 15th by Pamela G. Marrone. Prior to its name change, the firm was known as Marrone Organic Innovations Inc. It serves consumers internationally, with a focus on the United States.

The company offers molluscicide, miticide, insecticide, fungicide, herbicide and nematicide products. Its main crop protection products include Majestene, Venerate, Grandevo and Regalia. The company generates the majority of its revenue from the sale of the Venerate, Grandevo and Regalia products. It offers its products through distributors and commercial partners as well as directly through its sales force.

As mentioned above, the enterprise’s products include a bioinsecticide known as Zelto which protects turf, including greens, by promoting turf health by improving root and plant health; a bioinsecticide known as Venerate, which controls the sucking and chewing of mites and insects, as well as plant parasitic nematodes and flies; bio-fungicides like Stargus and Regalia, which improve quality and yields and protect against bacterial and fungal diseases; and a bionematicide dubbed Majestene, which controls soil-dwelling nematodes and some soil borne insects. It also offers a plant health product known as Haven, which decreases sun stress and dehydration. Furthermore, the enterprise offers a bioinsecticide known as Grandevo which also controls chewing and sucking insects.

The company recently advanced a trio of new bioherbicides in its research and development pipeline, which strengthens its positions as a leading provider of sustainable agricultural solutions. This move will play a crucial role in the company’s strategic growth plan, facilitating its entry into the billion-dollar weed control market, which will be good for investments into the firm.

Marrone Bio Innovations (MBII), closed Thursday’s trading session at $1.05, up 49.7006%, on 18,499,494 volume. The average volume for the last 3 months is 18.451M and the stock's 52-week low/high is $0.5492/$2.56.

Orphazyme A/S (ORPH)

MarketClub Analysis, Schaeffer's and QualityStocks reported earlier on Orphazyme A/S (ORPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Orphazyme A/S (NASDAQ: ORPH) (OTC: OZYMF) (FRA: 1TBD) is a biopharmaceutical firm that is engaged in the development of therapies for the treatment of neurodegenerative orphan indications, with a focus on lysosomal storage diseases.

The firm has its headquarters in Copenhagen, Denmark and was incorporated in 2009 by Thomas Kirkegaard Jensen,Martin Rahbek Kornum,Marja Jaattelaand Anders Morkeberg Hinsby. Prior to its name change, the firm was known as OrphazymeApS. It operates as part of the scientific research and development services industry, under the health care sector. The firm has three companies in its corporate family and serves consumers in Denmark.

The company is focused on developing new therapies to treat a family of genetic disorders. It develops the therapies by amplifying heat-shock proteins in diseases caused by protein aggregation and misfolding. The heat shock response is a natural defense mechanism in different cells. It collaborates with academic institutions in the United States and Europe.

The enterprise’s product pipeline comprises of an investigative medicinal formulation known as Arimoclomol which regulates the production of certain proteins in the cell. It is indicated for the treatment of four serious orphan diseases, namely Inclusion Body Myositis, Amyotrophic Lateral Sclerosis, Gaucher disease and Niemann-Pick disease Type C. This formulation helps misfolded proteins to recover their functional shape or remove them from the cells through the cells’ recycling system, i.e. the lysosomes, so they can’t form toxic aggregates.

The company’s arimoclomol candidate may soon receive approval for use by the FDA and the EU Market Authorization agency. This move will not only bring in more investments into the company but also boost its revenues.

Orphazyme A/S (ORPH), closed Thursday’s trading session at $0.9, up 37.4046%, on 15,587,194 volume. The average volume for the last 3 months is 15.535M and the stock's 52-week low/high is $0.5101/$77.77.

Yield10 Bioscience (YTEN)

StockMarketWatch, MarketBeat, TraderPower, StreetInsider, Schaeffer's, MarketClub Analysis, BUYINS.NET, QualityStocks and InvestorsUnderground reported earlier on Yield10 Bioscience (YTEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Yield10 Bioscience Inc. (NASDAQ: YTEN) (FRA: M6X3) is an agricultural bioscience firm that is focused on the development of technologies to enable increases in crop yield.

The firm has its headquarters in Woburn, Massachusetts and was incorporated in June 1992 by Oliver P. Peoples, Simon F. Williams and Anthony J. Sinskey. Prior to its name change in January 2017, the firm was known as Metabolix Inc. It operates as part of the agricultural inputs industry, under the basic materials sector. The firm serves consumers in Canada and the United States.

The company designs disruptive technologies to facilitate step-change improvements in crop yield for feed and food crops in order to enhance food security around the globe. It is party to license agreements with Bayer AG, Forage Genetics International LLC, J.R. Simplot, and GDM Seeds. The company generates most of its revenue from Canada.

The enterprise, via its Trait factory, is involved in the development of various crops including corn, soybean and canola to produce proprietary products and high value seed traits for the food and agriculture industries. It also develops Camelina sativa, an oilseed plant which has low fertilizer and water input, a short lifecycle and is drought resistant, making it a suitable rotation crop in the U.S.

The company recently announced its latest financial results, with its CEO noting that they were now focused on developing and launching differentiated Camelina varieties which could attract grower interest and demonstrate economic value. This will help bring in more investors into the company and create value for the company’s shareholders while bolstering its growth.

Yield10 Bioscience (YTEN), closed Thursday’s trading session at $4.3, up 4.878%, on 257,209 volume. The average volume for the last 3 months is 254,941 and the stock's 52-week low/high is $3.25/$16.88.

Relief Therapeutics (RLFTF)

BUYINS.NET reported earlier on Relief Therapeutics (RLFTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Relief Therapeutics Holding SA (OTCQB: RLFTF) (LON: 0QKQ) (SWX: RLF) is a biopharmaceutical firm that is engaged in the provision of therapeutic relief for patients living with severe illnesses with high unmet medical needs.

The firm has its headquarters in Geneva, Switzerland and was incorporated in 2013. It operates as part of the biotechnology industry, under the healthcare sector. The firm has four companies in its corporate family and serves consumers around the globe.

The company is focused primarily on the clinical development of proteins and peptides of engineered or natural origin, with a string scientific rationale or a history of clinical use, to address unmet medical needs.

The enterprise’s product pipeline comprises of a synthetic human VIP (vasoactive intestinal peptide) dubbed Aviptadil (RLF-100), with a multi-faceted mode of action in respiratory indications. This formulation is undergoing a phase II clinical trial evaluating its effectiveness in treating pulmonary sarcoidosis and 2 phase IIB and 3 clinical trials testing its efficacy in the treatment of acute respiratory deficiency caused by the coronavirus. It develops its Atexakinalfa low dosage interleukin-6 formulation, which exhibits functions in diverse organs and tissues. In addition to this, the enterprise is involved in developing RLF-100 for other indications in chronic and acute lung ailments.

The firm recently appointed a new member to its board of directors, who has extensive operational, strategic and commercialization experience at both emerging biotechnology firms and Big Pharma. The member’s addition may help the company enter its next stage of growth as per its strategy, which will boost revenues and expansion while also helping create shareholder value.

Relief Therapeutics (RLFTF), closed Thursday’s trading session at $0.0697, off by 1.831%, on 2,088,251 volume. The average volume for the last 3 months is 2.088M and the stock's 52-week low/high is $0.052/$0.41.

ParkerVision Inc. (PRKR)

Wall Street Resources, Money Morning, Marketbeat.com, TraderPower, The Street, StreetInsider, MarketBeat, BUYINS.NET, Greenbackers, OTCPicks, MicroCap Press, PennyStocks24, BullRally, PennyInvest, HotOTC, PennyStockVille, Equities.com, CoolPennyStocks, MadPennyStocks, Trading Concepts, StockRich, StockEgg, Stock Fortune Teller, StockOodles, StocksImpossible, Goldman Small Cap Research, Stocks That Move, Investing Futures, Hit and Run Candle Sticks, ProfitableTrading, GorillaTrades, First Penny Picks, TopPennyStockMovers, DrStockPick, TradersPro, The Motley Fool, StockMarketWatch, SmarTrend Newsletters, MonsterStocksPicks, OTCBB Journal, Stock Traders Chat, Penny Invest, Penny Sleuth, Stock Stars, Stock Market Watch, Stock Beast, QualityStocks, RedChip, ShazamStocks, SmallCapVoice and MarketClub Analysis reported earlier on ParkerVision Inc. (PRKR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ParkerVision, Inc. (OTCQB: PRKR) is focused on designing, developing and marketing of solutions for wireless products.

The firm has its headquarters in Jacksonville, Florida and was incorporated in 1989, on August 22nd by Jeffrey L. Parker. It operates as part of the semiconductors industry, under the technology sector. The firm serves consumers around the globe.

The company, through its ParkerVision GmbH subsidiary, is involved in developing integrated circuits and radio frequency technologies to be used in wireless communication products. It derives its revenue from the provision of engineering services, sales of its products, settlements from disputes of patent infringements and licensing of its intellectual property.

The enterprise provides low noise amplifiers, modulators, demodulators, tramsceivers and CDMA cellular chipsets. Its solutions are all based on its D2D (Direct-to-Data) technology, which is used in transmitting and receiving radio frequency communication signals in Internet of Things, WiFi (wireless internet), mobile telephone and many other applications. This technology also enables the overall performance direct conversion for radio frequency-to baseband and baseband-to radio frequency signals. Its radio frequency technologies allow for the accurate reception and transmission of radiofrequency carriers at low power, which enables extended battery life and specific performance, cost, size and packaging advantages. The enterprise also markets a WiFi product line which is consumer-distributed, under the Milo brand name.

The firm, which is focused on executing patent license and settlement agreements, is currently involved in a number of patent enforcement actions to protect rights of patents that it believes have been infringed upon by other parties.

ParkerVision Inc. (PRKR), closed Thursday’s trading session at $0.365, up 4.2857%, on 333,658 volume. The average volume for the last 3 months is 333,658 and the stock's 52-week low/high is $0.1699/$1.68.

Kidpik Corp. (PIK)

We reported earlier on Kidpik Corp. (PIK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kidpik Corp. (NASDAQ: PIK) is a subscription-based e-commerce firm that is involved in the sale of boys’ and girls’ apparel, accessories and footwear.

The firm has its headquarters in New York and was incorporated in 2015, on April 16th by Ezra Dabah. It operates as part of the clothing stores industry, under the consumer cyclical sector. The firm serves consumers in the United States.

The company is focused on offering head to toe outfits by designing every seasonal collection in-house, including shoes, from concept to box. It helps parents who’d like to shop coordinated outfits for their children find all they need in one store. This, in turn, helps save time through the delivery of mix and match, personalized outfits which have been curated by seasoned stylists and are ready to be worn, right out of the box.

The enterprise provides subscription boxes of clothing for both girls and boys (sizes 2T-16), which include 3 mix and match coordinated outfits which are personalized, based off of every member’s style preference. Members can shop for these boxes from the comfort of their homes and are usually given a week to decide what they’d like to return, keep or exchange. The enterprise delivers these outfits directly to a member’s door.

The firm recently launched its new spring collection which provides a range of stylish options from loungewear sets to trendy active wear. The firm’s home try-on experience business model not only allows parents to avoid the hassle of in-store shopping but also offers children fun and fashionable clothing for daily wear. This model may bring in more revenue as well as investors into the firm, which will be good for its growth.

Kidpik Corp. (PIK), closed Thursday’s trading session at $4.75, up 158.1522%, on 124,394,510 volume. The average volume for the last 3 months is 124.395M and the stock's 52-week low/high is $1.51/$10.4894.

Jones Soda (JSDA)

QualityStocks, SmarTrend Newsletters, MicrocapVoice, OTCPicks, Greenbackers, CoolPennyStocks, HotOTC, Hit and Run Candle Sticks, Stock Rich, BullRally, Penny Invest, StockEgg, Stockpalooza, Stock Traders Chat, SmallCapVoice, OTCReporter, PennyTrader Publisher, Bull Warrior Stocks, Stock Analyzer, SuperNova Elite, Hidden Stocks, TopPennyStockMovers, FNNO Newsletters, Dividend Opportunities, TopStockAnalysts, Marketbeat.com, TradersPro, Bull in Advantage, BestOtc, AllPennyStocks, CRWEPicks, Market Wrap Daily, StockHotTips, Momentum Traders, NanoCap Gems, Actual Gains, Wealthpire Inc., PennyOmega, PennyStockRumors.net, PoliticsAndMyPortfolio, PricelessPennyStocks, Stock Fortune Teller and Investor Update reported earlier on Jones Soda (JSDA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jones Soda Co. (OTCQB: JSDA) is focused on the development, production, marketing and distribution of beverages.

The firm has its headquarters in Seattle, Washington and was incorporated in 1986 by Peter M. van Stolk. It operates as part of the non-alcoholic beverages industry, under the consumer defensive sector. The firm serves consumers around the globe, with a focus on the United States and Canada.

The enterprise offers a premium non-carbonated beverage known as Lemoncocco; and a premium carbonated soft drink known as Jones soda. It also provides private label and co-branded products. The enterprise also provides fountain products, which include sugar free cola and cane sugar cola, lemon lime, root beer, orange and cream and sweetened cane sugar ginger ale. This is in addition to selling a number of products online, such as customized label sodas, candy and wearables, among other products. It licenses its trademarks to be used on products sold by various manufacturers. The enterprise distributes and sells its products via regional and national retail accounts, and a network of independent distributors, as well as via sandwich shops, delicatessens, restaurants, gas stores, convenience stores and grocery stores. It operates more than 200 Meijer stores in 6 states in the Midwest.

The company recently ventured into the cannabis space after it launched THC-infused sodas, gummies and syrups. This move not only positions it for significant growth in this burgeoning industry but will also bring in additional revenue into the company, help it extend its consumer reach and positively influence investments into the company.

Jones Soda (JSDA), closed Thursday’s trading session at $0.565, off by 5.8333%, on 312,638 volume. The average volume for the last 3 months is 312,638 and the stock's 52-week low/high is $0.401/$1.54.

The QualityStocks Company Corner

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food and beverage industries, today updated stakeholders on the company's key 2022 goals. PBI believes these goals are attainable in the current fiscal year and that their achievement will put the company on a rapid path to sustained growth, value increase and profitability. “In addition to the record number of instrument orders for a month, interest and engagement with our enabling BaroFold Platform protein refolding services has grown significantly over the past few months,” said Richard T. Schumacher, president and CEO of PBI. “We have also made measurable progress thus far in Q1 2022 in preparing for the commercialization of our revolutionary Ultra Shear Technology(TM) (‘UST(TM)’) Platform. Of particular note, we have significantly improved our balance sheet and solidified the foundation for our planned uplisting from the OTC Markets to a national exchange before year’s end. We have an exciting year ahead: we are prepared and ready for the challenge.” To view the full press release, visit https://ibn.fm/ABYkb

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Thursday’s trading session at $1.89, up 2.9973%, on 19,187 volume. The average volume for the last 3 months is 19,187 and the stock's 52-week low/high is $1.57/$4.98.

Recent News

Nemaura Medical Inc. (NASDAQ: NMRD)

The QualityStocks Daily Newsletter would like to spotlight Nemaura Medical Inc. (NASDAQ: NMRD).

  • Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, stroke
  • Companies in diagnostic space posting record revenues, double-digit YOY increases
  • Nemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology, companion mobile application and coaching programs
  • Competitor devices use microneedles coated with enzymes and polymers that can cause discomfort, trauma, and skin changes

Clinical research reveals that volatile blood sugar fluctuations are a primary risk factor for rapidly rising cases of metabolic syndrome - a cluster of diseases that include diabetes, dementia, cardiovascular issues, and stroke. Abbott (NYSE: ABT), a global healthcare company targeting the space, recently posted 4Q21 record revenue of $1.02 billion for its FreeStyle Libre diagnostic product, a 35% YOY increase. Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for chronic disease management, is strongly positioned to take a substantial market share with its recently launched Mikobo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear, and cost-effective. 

Nemaura Medical Inc. (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT®, is a wearable, non-invasive and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.

sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration in 2020 which is currently under review.

Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemaura’s skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring.

Technologies

Digital Solutions for Weight Loss and Potential Reversal of Type 2 Diabetes

This is a digital program that comes with more than a decade of clinical evidence demonstrating excellent efficacy. The company has combined this with its glucose-monitoring platform to bring a product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes.

Glucose Monitoring Solutions for Diabetes Prevention and Reversal

Over 420 million people worldwide are living with diabetes, and prediabetes cases total almost three times that number. Undoubtedly, diabetes is an urgent global health crisis. Combining clinical research with patient-friendly technology, Nemaura’s sugarBEAT product delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.

Continuous Lactate Monitoring for Athletic Performance (Non-Medical)

Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Well-trained athletes and those who regularly engage in sports are very efficient at faster lactate ‘recycling’ for extra energy (ATP). Nemaura expects to launch its lactate sensor to the sports and personal training market in 2022.

Continuous Lactate Monitoring in Disease State (Medical)

An increase in blood lactate levels is also a marker of critical disease states. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura has developed a lactate sensor that is being integrated into the company’s platform, which will be submitted for regulatory clearance upon completion of requisite clinical studies.

Continuous Temperature Monitoring for Viral Infection Detection and Disease Progression

A person’s body temperature says a lot about their health. Several diseases, including COVID-19, are characterized by an increase in body temperature, so temperature monitoring is a vital tool in the detection, diagnosis and prevention of the spread of disease. Nemaura is expecting to submit this adaptation of the device for regulatory clearance in 2022.

Market Opportunity

Obesity and diabetes are two of the major drivers of the current chronic disease epidemic. According to the International Diabetes Federation, there are more than 463 million people living with diabetes worldwide. In the U.S., about 28,000 people are diagnosed with diabetes every week, and more than 34 million suffer from diabetes. Another 88 million Americans have prediabetes. Other industrialized countries show similar numbers based on their populations. In the U.K., 4.8 million people have diabetes, with another diagnosed every two minutes. In Germany, 9.5 million have diabetes, with almost half estimated to be undiagnosed and so at greater risk.

On average, employers and insurers spend more than $9,000 annually on health care for an employee with diabetes, compared to $1,600 annually for a healthy employee. In the U.S. alone, more than $760 billion was spent on diabetes-related health care expenditures during 2019. Nemaura is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023.

Management Team

Dr. Faz Chowdhury has been CEO and chairman of the board of Nemaura Medical since 2013. He has more than 20 years of experience in the pharmaceutical and medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents and has authored textbook chapters on nano-biosciences for Wiley and Elsevier. He holds a master’s degree in microsystems and nanotechnology from Cranfield University, and a doctorate from the University of Oxford in nano-medicine and drug delivery.

Justin Mclarney is CFO at Nemaura. He most recently was the Senior Director, International Finance at Lands’ End Inc. He also worked for Office Depot as Senior Director of Finance for the largest business unit within the European group. Prior to that, he spent more than 10 years in practice, the majority of which was with Ernst & Young LLP.

Dr. Fred Schaebsdau is Vice President of Strategy & Strategic Alliances at Nemaura. He has more than 15 years of executive experience in the CGM, blood glucose monitoring and insulin delivery industries, including time with Abbott Diabetes Care, as General Manager of Dexcom Germany and at Roche Diabetes Care, where he was Senior Vice-President, Head of Global Strategy and Business Development. The firm he founded is the exclusive distributor in Europe, the Middle East and Africa of UniStrip®, the world’s first generic blood glucose test strip. He is licensed to practice medicine in the U.S. and Germany.

David Scott is Director of Commercial Development and Licensing at Nemaura. He is a trained chemist with over 35 years of experience in the pharmaceutical industry, including deal brokering, marketing, strategic planning, finance, business development and acquisitions. He has also provided licensing training for a number of multinational pharma companies and training organizations and is the author of best-selling report Scrip’s Practical Guide to Pharmaceutical Licensing.

Nemaura Medical Inc. (NASDAQ: NMRD), closed Thursday’s trading session at $4.11, up 7.874%, on 1,318 volume. The average volume for the last 3 months is 1,314 and the stock's 52-week low/high is $3.51/$17.40.

Recent News

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF)

The QualityStocks Daily Newsletter would like to spotlight Mydecine Innovations Group Inc. (MYCOF).

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is among organizations, working alongside researchers at the center of the veritable renaissance of psychedelics. “Mydecine is playing a crucial role in advancing the knowledge of the benefits of psychedelics by developing innovative first- and second-generation novel compounds for the treatment of mental health and addiction and sequentially collaborating with academics to undertake vital clinical research on them. So far, Mydecine has partnered with Johns Hopkins University to launch a clinical trial utilizing psilocybin for smoking cessation. Led by Principal Investigator Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University, the trial will evaluate the safety and efficacy of psilocybin-assisted psychotherapy using Mydecine’s lead drug candidate, MYCO-001, to treat tobacco addiction,” a recent article reads. The company is also planning a phase 2A trial focusing on PTSD in veterans and a multi-site smoking cessation trial, utilizing MYCO-001, led by Dr. Johnson. To view the full article, visit https://ibn.fm/n9ahZ. New research on addiction conducted by scientists from the University of California-Irvine has discovered links between metabolism and the circadian rhythm. The circadian clock relies on various interactions between systems to maintain regular timing and is entwined with metabolism. Environmental and/or genetic changes can distort communication between organs, which modifies the rhythm of various activities. Professor Emiliana Borrelli, the study’s author, stated that the group’s discovery showed a connection between metabolic dysfunction and substance-use disorders. Borrelli, who has specialized in molecular genetics and microbiology, collaborated with the late Professor Paolo Sassone-Corsi on this study. The discovery of the connection between addiction, circadian rhythm and metabolism shows how urgent it is to develop effective treatments for different mental health disorders in order to forestall the additional complications that could arise if a mental health condition isn’t effectively managed. Entities such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) are worthy of mention in this regard because they are focused on coming up with next-generation therapeutics to help patients who are unresponsive to the existing treatments. Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is among organizations, working alongside researchers at the center of the veritable renaissance of psychedelics. “Mydecine is playing a crucial role in advancing the knowledge of the benefits of psychedelics by developing innovative first- and second-generation novel compounds for the treatment of mental health and addiction and sequentially collaborating with academics to undertake vital clinical research on them. So far, Mydecine has partnered with Johns Hopkins University to launch a clinical trial utilizing psilocybin for smoking cessation. Led by Principal Investigator Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University, the trial will evaluate the safety and efficacy of psilocybin-assisted psychotherapy using Mydecine’s lead drug candidate, MYCO-001, to treat tobacco addiction,” a recent article reads. The company is also planning a phase 2A trial focusing on PTSD in veterans and a multi-site smoking cessation trial, utilizing MYCO-001, led by Dr. Johnson. To view the full article, visit https://ibn.fm/n9ahZ

Mydecine Innovations Group Inc. (NEO: MYCO) (NASDAQ: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction. Founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovations in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other mental health disorders.

Mydecine’s business model combines clinical trials and data outcome, technology and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine aims to responsibly fast-track the development of new medicines across its platforms, ultimately changing the way we treat mental health disorders. The company seeks to bridge the gap between the needs of patients and what the mental health care system currently provides.

Mydecine Innovations Group is headquartered in Denver with international offices in Canada and Europe.

Research and Technology

The invention and development of novel psychedelic and non-psychedelic molecules for medical use is an important part of Mydecine’s research strategy. The company uses molecules found in nature as building blocks to create improved second-generation drugs. This portfolio of new drugs represents major improvements to existing natural products and synthetics, including enhanced safety, efficacy, stability and dosing, as well as reduced side effects.

The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients, along with improved management of dosage and drug behavior for clinicians. Mydecine believes the multibillion-dollar market for mental health and addiction disorder medicines will soon be disrupted amid a resurgence of the study into psychedelics and data showing the immense benefits of these forms of medicine.

The company currently has four lead drug candidates which include various enhancements such as improved controllability, delivery mechanisms, safety, stability and shelf-life. The drug candidates are in clinical trials or in pre-trial stage as potential treatments to aid PTSD, substance abuse and smoking cessation.

Mindleap Health is a wholly owned subsidiary of Mydecine. The Mindleap platform is a virtual community that aims to foster the conscious and responsible adoption of psychedelic medicine into inner wellness. Users access the platform through the Mindleap app. Mindleap provides users with inner wellness resources to assist them in their daily mental-health journeys. The platform also seeks to support the conscious and trustworthy adoption of psychedelics into a widely accepted approach to mental health and inner wellness.

Market Outlook

The global smoking cessation market is expected to reach $63.99 billion by 2026, growing at a CAGR of 16.9 percent from 2018 to 2026. The market for psychedelic therapeutics is in its very early stages. Estimates of current market value and forecasts of expected value in future years are all over the map. Market forecasts range from $6.5 billion by 2030 with a CAGR of 15 percent, to more than $69 billion as soon as 2025, at a CAGR of 8.2 percent. What is clear is that interest in psychedelic therapeutic drugs is expanding rapidly.

Management Team

Joshua Bartch is Chief Executive Officer and Chairman of Mydecine Innovations Group. He is an experienced entrepreneur who co-founded AudioTranscriptionist.com and founded Denver-based dispensary Doctors Orders in 2009. He also founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the USA’s most significant and sophisticated legal cannabis wholesale platform.

Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, is the Chief Medical Officer of Mydecine. He was formerly Chief of Psychiatry for the Canadian Armed Forces, retiring in 2021 with the rank of colonel after 31 years of service. He began his career as a general duty medical officer and flight surgeon and spent his final 20 years of service as a psychiatrist. He maintains academic appointments at Dalhousie University and The University of Ottawa. He is the inaugural CF Brigadier Jonathan C. Meakins CBE, RCMAC, Chair in Military Mental Health at the Royal Ottawa Hospital.

Robert Roscow is Chief Scientific Officer of Mydecine. As a geneticist, he has spent his academic and professional careers looking for valuable and unique medicinal molecules found in nature. His innovations were applied at Canopy Growth and ebbu, where he ran those companies’ genetics divisions. He has leveraged his expertise to maximize industrial production of cannabinoids in a pharmacological context, resulting in multiple patent filings.

Damon Michaels is Chief Operating Officer of Mydecine. He previously consulted for various hemp businesses through his company, Emerald Baron. Before that, he served as GM for ebbu, the leading multi-platform cannabinoid research and technology firm based in Colorado. He has held leading roles with multiple large brands throughout the cannabis vertical. He also developed a national snowboard brand.

Mydecine Innovations Group Inc. (MYCOF), closed Thursday’s trading session at $0.091, off by 3.1915%, on 1,563,444 volume. The average volume for the last 3 months is 1.563M and the stock's 52-week low/high is $0.01/$2.20.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

A policy retreat that featured a panel discussion on advancing cannabis reform with a focus on the promotion of equity was attended last week by Democratic congressional legislators. The panel was moderated by Rep. Barbara Lee and was focused on the need to ensure that communities that were most affected by prohibition could benefit from the federal legalization of marijuana. Those in attendance discussed the Marijuana Opportunity, Reinvestment and Expungement (“MORE”) Act, which was sponsored by Jerrold Nadler, the House Judiciary chair. The cannabis industry, including companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS), looks forward to the translation of these discussions into concrete steps to end marijuana prohibition federally and address equity issues comprehensively.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Thursday’s trading session at $0.017, up 6.25%, on 2,315,568 volume. The average volume for the last 3 months is 2.316M and the stock's 52-week low/high is $0.014794/$0.1689.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO John Climaco provided a corporate presentation and participated in a moderated questions and answer session during the event. Berubicin, a novel anthracycline and the first in its drug class to appear to cross the blood-brain barrier, is CNS Pharmaceuticals’ lead drug candidate. “The company is currently developing treatments using Berubicin for serious brain and central nervous system oncology indications, including glioblastoma multiforme (‘GBM’), an aggressive and incurable form of cancer in the brain,” reads a recent article. The piece further discusses CNS Pharmaceuticals’ receipt of approval from swissethics, the umbrella organization of the cantonal Ethics Committee in Switzerland, for a pivotal Berubicin study for GBM. “Receiving approval from swissethics is a significant milestone for the company. Our stated goal is, and always has been, to see Berubicin approved for the treatment of glioblastoma, and this means globally,” Climaco said. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do, but how we do it as well.” To view the full article, visit: https://ibn.fm/63Fg1

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday’s trading session at $0.317, up 0.316456%, on 1,255,540 volume. The average volume for the last 3 months is 1.243M and the stock's 52-week low/high is $0.2453/$3.24.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth’s (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has made two significant changes to its board. The company named FLGC CEO Luis Merchan as board chair and announced that former Amazon executive Tim Leslie, who is currently serving as chair of Flora Growth’s advisory board, will join the company’s board of directors and audit committee. The company noted that the changes to the board indicate FLGC’s move toward becoming a U.S.-based issuer; the new appointments also support the company’s growth into new international marketsMerchan is replacing Bernie Wilson as board chair; Wilson will serve in an advisory capacity through 2022 to provide strategic guidance on capital markets and international expansion. “I am honored that our board has entrusted me with this role, and I believe it is a testament to what we have built together thus far,” said Flora Growth CEO and newly appointed chairman of the board Luis Merchan in the press release. “Our board has been incredibly supportive to date while always ensuring business decisions are in the best interest of our shareholders, and I am looking forward to continuing to work closely with them in this role. . . . We want to thank Bernie for his commitment to the growth of Flora during this formative time for our company and look forward to continuing to work with him as we continue to grow.” To view the full press release, visit https://ibn.fm/y37kJ

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Thursday’s trading session at $1.88, up 9.9415%, on 665,611 volume. The average volume for the last 3 months is 660,536 and the stock's 52-week low/high is $1.31/$21.45.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced changes in company leadership. According to the announcement, InMed chief financial officer Bruce Colwill is retiring, effective March 31, 2022; Colwill will serve as an advisor to the company through June 30, 2022, to ensure a smooth transition. The company has appointed Brenda Edwards as interim CFO while the company searches for a full-time replacement. Edwards has garnered more than 35 years experience to her new position, including more than two decades of experience as a chief financial officer; she has served in both private and public companies. Throughout her career, she has worked closely with merger and acquisitions, financings, managing high-growth situations and financial reporting. “I would like to thank Bruce for his invaluable leadership and significant contributions over almost three years including managing our transition to the Nasdaq and several financings to ensure the long-term growth of the company,” said InMed president and CEO Eric A. Adams in the press release. “I wish him the very best and appreciate his continued assistance to ensure a smooth transition. I am delighted to welcome Brenda to the company. Brenda comes with extensive experience and will be an excellent fit to help us through this transitional period.” To view the full press release, visit https://ibn.fm/kc2Z2

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Thursday’s trading session at $0.7402, up 5.8033%, on 58,905 volume. The average volume for the last 3 months is 58,891 and the stock's 52-week low/high is $0.6521/$4.38.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

  • More than 60% of American who suffer from mental health conditions want access to psychedelic options
  • Growing number of cities, states looking at decriminalizing use of psychedelic medicine
  • Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space

The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention to. 

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Thursday’s trading session at $0.8354, up 1.878%, on 255,901 volume. The average volume for the last 3 months is 245,493 and the stock's 52-week low/high is $0.7738/$3.38.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

The attack on Ukraine by Russia has created a crunch for the electric vehicle industry. The war has led to a sudden spike in gasoline prices just as electric car makers are looking to fulfill their inventory of greener vehicles. Within the last two weeks, Tesla has received approval to set up a battery factory in Germany while Honda, Ford and Stellantis have announced that they are increasing their rates of electric vehicle production. The skyrocketing oil price is the highest it has been in the last 14 years. The surge is expected to drive consumer interest in favor of green alternatives, following similar trends seen last year during UK’s fuel shortages, which increased online searches of electric cars. As a result, the total number of electric vehicle (EV) registrations tripled to almost 18%.In times of strife, many opportunities arise. We wait to see how EV companies such as Mullen Automotive Inc. (NASDAQ: MULN) will innovatively navigate the challenges brought by the Ukraine war and the attendant supply chain issues.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday’s trading session at $2.44, up 39.4286%, on 514,822,304 volume. The average volume for the last 3 months is 514.822M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

A recent survey released by the American Bankers Association has found that almost 70% of Americans are in favor of allowing financial institutions to work with cannabis businesses without the threat of being penalized. The poll, which was conducted by Morning Consult, interviewed more than 2,000 adults between February 18–19, 2022. The survey asked respondents a pair of questions on cannabis banking. The first asked respondents whether they support or oppose allowing cannabis businesses to “access traditional banking services, like a checking account or business loan, in states where cannabis is now legal.” The poll found that 65% were in favor of this, with only 15% opposing it. The second question asked respondents whether Congress needed to pass a bill that would accomplish this reform, with 68% indicating that legislators did need to approve the measure. Many hope that the banking measure will soon be approved, as the number of banks working with legal cannabis businesses increases. As the relationship between mainstream banks and licensed marijuana companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is allowed under federal law, we are likely to see the industry grow at a faster rate since companies will have access to needed services, including bank loans to fund their growth.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Thursday’s trading session at $0.288, up 5.2901%, on 100,616 volume. The average volume for the last 3 months is 100,616 and the stock's 52-week low/high is $0.25/$1.30.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Last month, we saw Russia invade Ukraine after years of conflict. This invasion has raised questions about the flow and cost of fuel to the advanced nuclear reactors in the United States, which are considered a primary tool in the fight against climate change. When issuing an executive order to block imports of natural gas and crude oil from Russia earlier this month, President Biden did not include uranium on the list. However, the White House has been conferring with the nuclear sector about the possible impact of imposing sanctions on Rosatom, a Russian-based nuclear energy company. Imposing sanctions on this state-owned corporation may present long-term challenges for the fleet of reactors in the U.S., which need low-enriched uranium to operate. This crisis also offers opportunities for setting up domestic facilities where the uranium mined by local companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) can be further processed for use in various applications, such as feeding advanced nuclear energy reactors with the fuel they need.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Thursday’s trading session at $9.47, up 14.234%, on 8,490,516 volume. The average volume for the last 3 months is 8.422M and the stock's 52-week low/high is $4.32/$11.39.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

  • Mental health conditions affect millions of people globally, some of whom are resistant to existing treatments
  • In the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatment
  • Delic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes showing its therapeutic effectiveness
  • Delic hopes to reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments

The World Health Organization (“WHO”) reports that mental health conditions, including depression, bipolar disorder, anxiety, schizophrenia, dementia, developmental disorders, post-traumatic stress disorder (“PTSD”), and more, are on the rise worldwide. Data from the ten years to 2017 showed a 13% increase in mental health conditions and substance use disorders, with the former causing disability among patients – for one in five years (https://ibn.fm/5gZto). A 2017 study estimated that about 10.7% of the world population, or 792 million people, lived with a mental health disorder (https://ibn.fm/pSrvt). Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and company CEO and cofounder Matt Stang were spotlighted during a recent segment of the Jesse Tee Show. During the interview, Stang provided a summary of the journey to his present position with Delic Holdings, noting that he started as an intern with “High Times.” He worked in several positions at the publication, eventually buying out one of the owners. Stang also discussed the therapeutic potential of psychedelic compounds and provided a brief history of Delic. “In 2016, we put ‘High Times’ up for sale. . . and sold it to a private equity group,” said Delic Holdings CEO and cofounder Matt Stang during the interview. “I had a wonderful experience at Burning Man and saw the incredible way that psychedelic culture was going mainstream. . . .There were bankers, lawyers, celebrities, and everyone there at 3 in the morning was clearly on some form of psychedelic substance having a great time being removed from the commodification of the everyday world. . . . Having spent time before that looking at psychedelics. . . . we saw a moment in time when the rest of the world hadn’t caught up to what was happening. We decided that it was time to use our talents for something good — to push the mainstreaming of psychedelics and psychedelic wellness. We created Delic a month later.” To listen to the full interview, visit https://ibn.fm/JdH0f. To view the full press release, visit https://ibn.fm/idcaz. A new study has found that MDMA-assisted therapy may extend and improve the lives of patients suffering from severe and chronic PTSD and also decrease the cost of healthcare. MDMA is a drug known to alter an individual’s mood and perception; it is commonly referred to as molly or ecstasy. Elliot Marseille, the study’s corresponding author, stated that he launched the Global Initiative for Psychedelic Science Economics together with his colleagues from UC Berkeley and UCSF after seeing encouraging results on psychedelic-assisted therapy from different clinical trials. Marseille, who is also the founder of Health Strategies International, explained that the aim of the study was to offer accurate and policy-relevant economic analyses on psychedelic therapies, noting that the researchers focused on MDMA therapy because the U.S. Food and Drug Administration may soon approve its use as a legal treatment. It is fathomable that psychedelic-based mental health treatments, such as those provided by companies including Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF), can save the country millions since these treatments are effective in tackling the mental condition from its root, thereby minimizing the need for ongoing care. A new study has found that MDMA-assisted therapy may extend and improve the lives of patients suffering from severe and chronic PTSD and also decrease the cost of healthcare. MDMA is a drug known to alter an individual’s mood and perception; it is commonly referred to as molly or ecstasy. Elliot Marseille, the study’s corresponding author, stated that he launched the Global Initiative for Psychedelic Science Economics together with his colleagues from UC Berkeley and UCSF after seeing encouraging results on psychedelic-assisted therapy from different clinical trials. Marseille, who is also the founder of Health Strategies International, explained that the aim of the study was to offer accurate and policy-relevant economic analyses on psychedelic therapies, noting that the researchers focused on MDMA therapy because the U.S. Food and Drug Administration may soon approve its use as a legal treatment. It is fathomable that psychedelic-based mental health treatments, such as those provided by companies including Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF), can save the country millions since these treatments are effective in tackling the mental condition from its root, thereby minimizing the need for ongoing care.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Thursday’s trading session at $0.07132, off by 0.861829%, on 21,408 volume. The average volume for the last 3 months is 21,408 and the stock's 52-week low/high is $0.0533/$0.495.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.